anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Breast milk is recommended for most infants by the American Academy of Pediatrics as there are multiple benefits. However, some infants, such as extremely premature infants, are unable to receive enteral nutrition for a variety of clinical reasons. In order provide these infants with some of the benefits of mother's milk, a novel adjunctive therapy called oral care has been developed. Oral care consists of applying mother's breast milk to the buccal mucosa. Oral care has been studied in the premature infant population and been shown to improve both feeding tolerance and to provide immune protection. Although only studied in the premature population, many institutions including Texas Children's Hospital have adopted oral care as a standard of care for all infants as oral care poses minimal risk to the patient and has many potential benefits. Gastroschisis is a rare abdominal wall defect. Although the survival rate for infants with gastroschisis is high, there are significant morbidities related to feeding intolerance and infection. The investigators believe that this population of patients will also benefit from oral care.

The mechanism by which oral care works is not completely understood. It is theorized that oral care stimulates the oropharyngeal-lymphoid tissue in the buccal mucosa. Additional mechanisms include alteration of the intestinal microbiome. The intestinal microbiome is the millions of microorganisms that line the intestine. Normally, there is a mutually beneficial relationship. The intestinal microbiome is altered by many factors, including gestational age, antibiotic use, type of delivery, etc. Alterations in the microbiome can be detrimental and cause severe diseases such as necrotizing enterocolitis. Thus, far studies have shown that oral care alters the oral microbiome to include more healthy bacteria. The investigators believe that oral care with breast milk will be associated with a more diverse fecal microbiota. Finally, the investigators will evaluate a novel mechanism by which the investigators believe oral care is protective; via increased salivary gland secretion of certain proteins important for healing. In particular, saliva contains vascular endothelial growth factor, which is important for palatal wound healing and alimentary tract healing.
Methods and systems are disclosed that involve monitoring use by a user of a device, of an application associated with the device, or a combination thereof. The device is configured to provide therapy to the user. The application is configured to provide control of the device, to provide information to the user related to the therapy, or a combination thereof. The methods and systems also involve determining whether one or more milestones associated with an incentive scheme for the user have been satisfied by the use. The incentive scheme relates to continued provisioning of the therapy to the user by the device. The methods and systems also involve unlocking functionality of the device, the application associated with the device, or a combination thereof for the user based on satisfaction of at least one of the one or more milestones.
This study was aimed to investigate the effect of hydrogen-rich solution (HRS) on acute radiation pneumonitis (ARP) in rats. The ARP model was induced by X-ray irradiation. Histopathological changes were assessed using HE and Masson stains. Inflammatory cytokines were detected by ELISA. Immunohistochemistry and flow cytometry were performed to quantify macrophage (CD68) levels and the M2/M1 ratio. Western blot analysis, RT-qPCR, ELISA and flow cytometry were used to evaluate mitochondrial oxidative stress injury indicators. Immunofluorescence double staining was performed to colocalize CD68/LC3B and p-AMPK-α/CD68. The relative expression of proteins associated with autophagy activation and the adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin/Unc-51-like kinase 1 (AMPK/mTOR/ULK1) signaling pathway were detected by western blotting. ARP decreased body weight, increased the lung coefficient, collagen deposition and macrophage infiltration and promoted M1 polarization in rats. After HRS treatment, pathological damage was alleviated, and M1 polarization was inhibited. Furthermore, HRS treatment reversed the ARP-induced high levels of mitochondrial oxidative stress injury and autophagy inhibition. Importantly, the phosphorylation of AMPK-α was inhibited, the phosphorylation of mTOR and ULK1 was activated in ARP rats and this effect was reversed by HRS treatment. HRS inhibited M1 polarization and alleviated oxidative stress to activate autophagy in ARP rats by regulating the AMPK/mTOR/ULK1 signaling pathway.
Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m\^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will be assigned to the Waitlist Control group. The subjects will be offered the intervention after completion of the 12-week waiting period. The subjects will then begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
FIELD: adsorbents and filters. SUBSTANCE: porous material having pores more   in size is used as carrier, zeolite having pores less than   in size is used as molecular screen. Analcite having pores   in size may be used as mentioned above zeolite, heat-resistant material may be used as carrier. Said carrier may have fibrous structure, its pores may have canal structure. EFFECT: improves quality of desired product. 5 cl, 5 dwg
Patients receive ofatumumab IV over 4-6 hours on days 1, 8, 15, and 22 of courses 1-2, and on day 1 of courses 4-7. Beginning on course 2, patients also receive dinaciclib IV over 2 hours on days 2, 8, and 15 of course 2, and on days 1, 8, and 15 of courses 3-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
NEW MATERIAL:The polypeptide of formula I . USE:Drug having growth hormone secretion accelerating activity. An antiulcer agent. A remedy for wound. Effective to various growth hormone deficiency diseases such as microplasia. PREPARATION:The peptide fragment of formula II is condensed with the peptide fragment of formula III having protecting group, and the condensation product is condensed with the peptide fragment of formula IV having protecting group. The product is further condensed with protected glutamine and leucine, and then successively with the peptide fragments of formula V - formula IX each having protecting group, and finally, the protecting groups are removed to obtain the objective polypeptide of formula I . All amino acids in the formulas are L-isomers.
Polyploidy is typically described as the condition wherein a cell or organism has more than two complete sets of chromosomes. Occurrence of polyploidy is a naturally occurring phenomenon in the body's development and differentiation processes under normal physiological conditions. However, in pathological conditions, the occurrence of polyploidy is documented in numerous disorders, including cancer, aging and diabetes. Due to the frequent association that the polyploidy has with these pathologies and physiological process, understanding the cause and consequences of polyploidy would be beneficial to develop potential therapeutic applications. Many of the genetic and epigenetic alterations leading to cancer, diabetes and aging are linked to signaling pathways. Nonetheless, the specific signaling pathway associated with the cause and consequences of polyploidy still remains largely unknown. Mammalian/mechanistic target of rapamycin (mTOR) plays a key role in the coordination between eukaryotic cell growth and metabolism, thereby simultaneously respond to various environmental inputs including nutrients and growth factors. Extensive research over the past two decades has established a central role for mTOR in the regulation of many fundamental cellular processes that range from protein synthesis to autophagy. Dysregulated mTOR signaling has been found to be implicated in various disease progressions. Importantly, there is a strong correlation between the hallmarks of polyploidy and dysregulated mTOR signaling. In this review, we explore and discuss the molecular connection between mTOR signaling and polyploidy along with its association with cancer, diabetes and aging. Additionally, we address some unanswered questions and provide recommendations to further advance our understanding of the intricate relationship between mTOR signaling and polyploidy.
A drinking reminder method is implemented by an electronic apparatus. The apparatus includes a scale pan, a weight sensor, an analog/digital (A/D) converter, a display screen and a keypad. The keypad comprising a power key, a reset key and a switching key. The weight sensor senses an analog pressure signal when a cup filled with water is placed on the scale pan, and the A/D converter converts the analog pressure signal to a digital weight signal. A total weight of the cup filled with water is measured according to the digital weight signal, and a cumulative water intake volume and a water shortage volume of a user. The display screen displays the cumulative water intake volume and the water shortage volume on to remind the user to drink water.
The cannabidiol will be administered as an oral solution to be mixed in any fluid. The formulation is 100 mg/ml. It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
The invention discloses a Chinese herbal preparation for treating acute tracheobronchitis. The Chinese herbal preparation is prepared from dried ginger, rhizoma pinelliae preparata, platycodon grandiflorum, asarum sieboldi, hot pepper, dragon blood, safflower carthamus, wintergreen oil, cinnamon leaf oil, clove oil, citionella oil and liquorice. The invention further discloses a preparing method of the Chinese herbal preparation for treating acute tracheobronchitis. The preparing method comprises the steps of smashing and evenly mixing dried ginger, rhizoma pinelliae preparata, platycodon grandiflorum, asarum sieboldi, hot pepper, dragon blood, safflower carthamus and liquorice, soaking the mixture in water, conducting decoction and filtration, and concentrating filter liquor to obtain clear paste; adding wintergreen oil, cinnamon leaf oil, clove oil and citionella oil to the clear paste, and mixing the mixture evenly to obtain the Chinese herbal preparation for treating acute tracheobronchitis. The invention further discloses the application of the Chinese herbal preparation for treating acute tracheobronchitis in preparing drugs for treating bronchopneumonia and chronic bronchitis. The Chinese herbal preparation for treating acute tracheobronchitis has mild side effects and a good curative effect, the average cure rate within five days is as high as 90.4%, and the average total effective rate is as high as 98.8%.
Patients will receive 2,000 impulses of placebo radial shockwave per week, without any energy flow intensity. Frequency of 8Hz will appear in the screen. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
PROBLEM TO BE SOLVED: To provide an ophthalmic device having therapeutic agent delivery capability and to provide use of the same.SOLUTION: The present invention is directed to an ophthalmic device that is at least partially formed of an ophthalmic material. The ophthalmic material is typically acrylic, hydrophobicity, or both. The ophthalmic material is typically loaded with a therapeutic agent. In preferred embodiments of the invention, the therapeutic agent and the ophthalmic material are hydrophobic for assisting in loading the material with the agent and for assisting in prolonging the release of the therapeutic agent from the ophthalmic material. The ophthalmic device may be suitable for location within an eye or location upon an outer surface of the eye. In a preferred embodiment, the ophthalmic device, which will be partially or entirely formed of the ophthalmic material, is an IOL or a device suitable for location within the eye along with an IOL.
Gastroparesis is a gastrointestinal disorder characterized by significant prolongation of gastric emptying time caused by impaired motility of the stomach. Its estimated prevalence is 24.2 per 100 000 people. However, the prevalence of gastroparesis in Asian countries is unknown due to a limited number of epidemiological studies and significant phenotypic variability of the Asian population in these studies. Analysis of previous research on gastroparesis and functional bowel disorders reveals the possibility of an increased prevalence among Asian individuals. A comparison of ethnic constituents between the recent United Kingdom gastroparesis study and its mother database has demonstrated a higher prevalence of gastroparesis among British Asian patients when compared with British Caucasian patients. An estimated gastroparesis prevalence in the Asian population can be calculated by identifying the individuals who are likely to demonstrate a delayed gastric emptying from all diagnosed functional dyspepsia patients. We suggest that gastroparesis tends to be underdiagnosed in Asians due to a lack of studies on gastroparesis in the Asian continent, a lack of knowledge among practitioners, and poor availability of scintigraphy testing as well as limited therapeutic options for this disease. Given the high probability of Asian predominance in gastroparesis and its disease impact on quality of life, epidemiological research focusing on the Asian population is required.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to the field of preparing the preparation of vegetable origin used for elimination or relief of pain. Invention proposes an agent in the form of alcoholic extract prepared of elecampane leaves or stems, or seeds, or roots in the ratio raw : extractant = 1: 10 using 40% ethyl alcohol as an extractant. The proposed agent shows an equal activity with relation to analgin being without danger of development of adverse effects and negative results. EFFECT: high analgetic activity, absence of adverse effects. 3 cl, 2 tbl
Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone. If they tolerate sl buprenorphine, on day 4 they will be administered an 8 mg dose of BRIXADI on day 5 (if they do not tolerate sl buprenorphine/naloxone we will extend sl dosing). During week two of dosing, they will receive 16 mg dose of BRIXADI will be given, based on the participant's response to the previous dose. During week three of dosing, they will receive a 24 mg dose of BRIXADI. During week four they will be administered a monthly dose of 64mg, 96mg, or 128mg. In all cases, the dose selected will be based on their response to the previous weeks' dose. We will endeavor to get you on the 96 mg or 128 mg monthly dose as there is a lack of opioid blockade data for the 64 mg monthly dose.
Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
The invention discloses a traditional Chinese medicinal composition for preventing and treating postpartum dysgalactiae syndrome in sows. The traditional Chinese medicinal composition consists of the following raw material components in parts by weight: 35-50 parts of corn stigma, 5-10 parts of ricepaperplant pith, 5-10 parts of uniflower swisscentaury root, 8-15 parts of radix rehmanniae praeparata, 5-10 parts of rhizoma ligustici wallichii, 5-10 parts of herba taraxaci, 5-10 parts of radix astragali, 5-10 parts of liquorice root and 5-10 parts of radix angelicae sinensis, and further consists of proper amount of adjuvants which are commonly used in medicines. The traditional Chinese medicinal composition, in accordance with production conditions and market demands, can be prepared into various orally taken dosage forms such as granules, oral liquid, powder, tablets and the like. Based upon clinical tests, the traditional Chinese medicinal composition can be used for effectively preventing and treating the postpartum dysgalactiae syndrome in sows. The traditional Chinese medicinal composition disclosed by the invention, as a pure traditional Chinese medicinal preparation, is free from withdrawal time and drug residue and is capable of guaranteeing the safety of animal foods. The traditional Chinese medicinal composition has a broad application prospect in the field of veterinary drug industrial production.
PURPOSE:A liver protecting drug comprising a specific oligomethionine or its ester as an active ingredient. CONSTITUTION:A liver protecting agent containing an oligomethionine having <=10 polymerization degree or its ester (1-4C alkyl ester) as an active ingredient. For example, it is useful for acute hepatitis, chronic hepatitis, epidemic hepatitis, jecur adiposum, liver cirrhosis, drug poisioning, etc. A dose is 1-10g/ person.day in case of oral administration and the drug can be administered dividedly once - several times. A dose is tens mg - several hundreds mg/person. day in case of injection, and the drug can be administered dividely once - several times. The oligomethionine having a desired polymerization degree or its ester as the active ingredient is obtained by bonding successively methionine or by polymerizing methionine enzymatically.
FIELD: medicine, organic chemistry. SUBSTANCE: invention relates to inhibitor of intima hypertrophy. Inhibitor has hydroxyindole derivative as an active component of the formula (I)   or its salt where R′ means hydrogen atom, phenyl group that can be substituted with lower alkyl group, lower alkoxy-group, lower alkylaminoalkoxy-group, hydroxyl group, amino-group, lower alkylamino-group or halogen atom, or pyridyl group that can be substituted with lower alkyl group, lower alkoxy-group, lower alkylaminoalkoxy-group, hydroxyl group, amino-group, lower alkylamino-group, halogen atom, lower alkoxycarbonyl group or carboxyl group; phenyl group that can be substituted with, or pyridyl group that can be substituted with lower alkyl group, lower alkoxy-group, lower alkylaminoalkoxy-group, hydroxy-group, amino-group, lower alkylamino-group, halogen atom, lower alkoxycarbonyl-group or carboxyl group; hydrogen atom, lower alkyl group, benzyl group or benzenesulfonyl group that can be substituted or acyl group; hydrogen atom, lower alkoxy-group, halogen atom, amino-group, lower alkylamino-group, carboxyl group, lower alkoxycarbonyl group, phenylcarbamyl group that can be substituted, or trifluoromethyl group; CH-group or means the whole number from 0 to 4 that means a number of substituents and double dotted/ /unbroken line means a simple bond or a double bond. Agent shows the strong inhibitory effect directed against intima hypertrophy and used as an agent for prophylaxis/treatment/ /relaxation of proliferative vascular diseases as, for example, restenosis after PTCA, arteriosclerosis, peripheral embolia and angiitis. Invention relates to also the use of hydroxyindole derivative for synthesis of inhibitor of intima hypertrophy, composition for inhibition of intima hypertrophy and the method of prophylaxis and treatment of patients with intima hypertrophy. Described inhibitor is the effective agent used for prophylaxis of vessel restenosis after angioplasty and for treatment of patients with arteriosclerosis. EFFECT: enhanced effectiveness of inhibitor described above. 9 cl, 2 dwg, 24 tbl, 18 ex
1. A compound of the formula:   or fumaric acid salt thereof. 2. The compound of claim 1, which is the compound of the formula:   3. A process for preparing a compound of the formula:   or fumaric acid salt thereof, which comprises (1) reacting a compound of the formula:   or its reactive derivative at the carboxy group or a salt thereof with a compound of the formula:   or its reactive derivative at the amino group or a salt thereof to give a compound of the formula:   or fumaric acid salt thereof, or (2) reacting a compound of the formula :   or a salt thereof other than fumaric acid salt thereof with fumaric acid to give a compound of the formula:   4. A pharmaceutical composition comprising a compound of claim 1 as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient. 5. A method for treating or preventing Tachykinin-mediated diseases which comprises administering an effective amount of a compound of claim 1 to a human being or animals. 6. A compound of claim 1 for use as a medicament. 7. Use of a compound of claim 1 for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases. 8. A compound of the following general formula:   wherein R<1> is trihalo(lower)alkyl, R<2> is trihalo(lower)alkyl, R<3> is indolyl(lower)alkyl,   in which R<5> is hydrogen or lower alkoxycarbonyl, R<6> is hydrogen or lower alkanoyl, R<7> is hydrogen, lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy(lower)alkanoyl, cyclo(lower)alkylcarbonyl, aroyl or lower alkylsulfonyl, or its pharmaceutically acceptable salt.
The invention provides a novel traditional Chinese medicinal compound Subing (quick effect heart rescue) spraying agent and its preparation method and belongs to the field of biomedicine, wherein the Subing (quick effect heart rescue) spraying agent has a good curative effect of resisting coronary angina pectoris. The problem of dissolving borneol with levant storax oil is solved by a new technology and a new method. The prescription is composed of styrax, borneol, a solubiliser, an absorption enhancer and a solvent. By the simple new technology of dissolution, homogenization and the like, borneol which is completely insoluble in water and levant storax oil which is not miscible with water phase are dissolved together in an oral water-soluble base so as to obtain an oral solution which is uniform and transparent without layers and suspension. The spraying agent or aerosol prepared in the invention can be quantitatively and directly sprayed into mouth or sprayed under tongue or directly sprayed into nasal cavity. In comparison with a solid preparation, the spraying agent prepared by styrax and borneol for oral administration has advantages of fast absorption and rapid effect, can perform a curative effect better and faster, is applicable to be taken by patients with angina pectoris during the acute phase. By the adoption of the preparation method provided by the invention, the effect onset time is greatly shortened within 60 seconds. The preparation method provides a good therapeutic novel medicine for currently high frequency and high occurrence of heart disease in our country.